Get the Stockscreener App
1.30
2.99%
-0.04
Pre-market:
1.31
0.01
+0.77%
Entera Bio Ltd stock is traded at $1.30, with a volume of 285.76K.
It is down -2.99% in the last 24 hours and up +8.33% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.34
Open:
$1.32
24h Volume:
285.76K
Relative Volume:
1.52
Market Cap:
$59.61M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-3.8235
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
-17.72%
1M Performance:
+8.33%
6M Performance:
-39.81%
1Y Performance:
-34.34%
1-Day Range:
$1.24
$1.51
1-Week Range:
$1.24
$1.59
52-Week Range:
$1.00
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.30 | 61.45M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Entera Bio (NASDAQ:ENTX) Stock Price Down 3%Here's What Happened - MarketBeat
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Bitget
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
Entera Bio Submits Streamlined Phase 3 Plan for EB613 - TipRanks
Entera Bio submits streamlined Phase 3 protocol for EB613, seeks 12-month hip BMD primary endpoint - TradingView
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis - marketscreener.com
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate - GlobeNewswire
Debt to equity ratio of Entera Bio Ltd. – HAM:5DT - TradingView
Aug Intraday: Is Entera Bio Ltd stock risky to hold nowMarket Volume Report & High Return Stock Watch Alerts - baoquankhu1.vn
ENTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ENTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Short Bowel Syndrome Market: High-Growth Opportunities for Investors to 2034DelveInsight - openPR.com
Entera Bio CEO to join Leerink 2026 healthcare fireside chat - Stock Titan
Buyback Watch: Is Entera Bio Ltd stock risky to hold nowTrade Ideas & Low Volatility Stock Suggestions - baoquankhu1.vn
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woma - GuruFocus
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX) - TipRanks
Nasdaq Moves: Is BHRPRB impacted by rising ratesJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
ENTXEntera Bio Ltd Latest Stock News & Market Updates - Stock Titan
Will Entera Bio Ltd. stock see insider buyingJuly 2025 Pullbacks & Accurate Buy Signal Alerts - mfd.ru
Entera Bio names former Pfizer executive Geno Germano as board chair - MSN
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours - Benzinga
Entera Bio (ENTX) director buys 5,000 shares in open market trade - Stock Titan
Is Entera Bio Ltd. a good stock for dollar cost averaging2025 Support & Resistance & Verified Technical Trade Signals - mfd.ru
Will Entera Bio Ltd. stock outperform growth indexesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Is Entera Bio Ltd. stock risky to hold nowWeekly Investment Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug Momentum: Can Entera Bio Ltd deliver consistent dividendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
Why Entera Bio Ltd. stock could rally in 2025Chart Signals & Expert Approved Momentum Trade Ideas - mfd.ru
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Asianet Newsable
Will Entera Bio Ltd. stock gain from government policiesJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
Insider Buying: Steven Rubin Acquires Shares of Entera Bio Ltd (ENTX) - GuruFocus
Sean Ellis Buys 18,000 Shares of Entera Bio (NASDAQ:ENTX) Stock - MarketBeat
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq
Entera Bio Ltd. Board Members and CEO Purchase Company Shares Amid Ongoing Development of Oral Therapies - Quiver Quantitative
Entera Bio insiders are buying more of their own shares on market - Stock Titan
Why Entera Bio Ltd. (5DT) stock is favored by hedge funds2025 Investor Takeaways & Accurate Trade Setup Notifications - mfd.ru
Entera Bio Names Geno Germano Independent Board Chairman - The Globe and Mail
Entera Bio appoints Geno Germano as board chairman By Investing.com - Investing.com South Africa
Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones - marketscreener.com
Entera Bio Ltd: Geno J. Germano appointed as chairman of Entera Bio - marketscreener.com
Entera Bio Ltd. Announces Board Changes - marketscreener.com
Entera Bio Attracts Former Pfizer Group President as It Enters a New Phase (NASDAQ: ENTX) - GuruFocus
Entera Bio appoints Geno Germano as board chairman - Investing.com
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - The Manila Times
Entera Bio Ltd. Appoints Geno J. Germano as New Chairman of the Board as Company Advances Oral Peptide Pipeline - Quiver Quantitative
Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Finviz
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Steven D. Rubin - Longbridge
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
| LIEBERMAN GERALD M | Director |
Apr 01 '25 |
Option Exercise |
1.00 |
23,952 |
23,952 |
300,160 |
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):